MagForce (DB: MF6)

Currency in EUR

Last close As at 03/02/2023

EUR0.02

0.01 (100.00%)

Market capitalisation

Edison Investment Research is terminating coverage on MagForce. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Sector

Healthcare

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (73.9) (99.0) (99.5)
Relative (75.2) (99.0) (99.4)
52 week high/low €3.6/€0.0

Financials

MagForce is a German med-tech firm with a CE-mark approved nanotechnology cancer treatment. This consists of NanoTherm (iron nanoparticles), Nanoplan (software) and NanoActivator (a device that produces a powerful magnetic field to heat the nanoparticles, which destroys or sensitises tumour cells to therapy).

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2020A 0.6 19.3 (9.7) (0.35) N/A N/A
2021A 0.4 (6.1) (8.9) (0.30) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

Healthcare

Executive interview – Magforce at EKF 2019

Healthcare

MagForce — 2019 a pivotal year

Healthcare

MagForce — 2019 a pivotal year

Healthcare

MagForce — NO SUBTITLE

Healthcare

MagForce — Update

Healthcare

MagForce — Steady progress

Healthcare

MagForce — Steady progress

Healthcare

Drug delivery platforms

Healthcare

Neuroscience comeback

Consumer

IPO apocalypse

TMT

ESG, moving beyond the box tick

Healthcare

Artificial intelligence in drug discovery

Healthcare

Edison Exhibits- antibiotic development

Healthcare

The next wave in AMD

Healthcare

Cannabinoid Therapies- The coming retail wave

Healthcare

The diagnostics sector

Healthcare

ASCO 2017